Homepage
Author:
Altesa Biosciences Inc.
Posted Date:
March 19, 2026
Altesa BioSciences’ Treatment for Rhinovirus Infections in People with Respiratory Conditions, Vapendavir, Selected for Oral Presentation at the International Society for Antiviral Research Conference (ICAR) 2026
Altesa Biosciences Inc.
March 19, 2026
Altesa BioSciences Closes Oversubscribed $75 Million Series B Financing to Transform Treatment of Chronic Lung Diseases
Altesa Biosciences Inc.
February 19, 2026